Regulation of Bile Acid and Cholesterol Metabolism by PPARs
暂无分享,去创建一个
[1] O. Barbier,et al. Lipid-activated transcription factors control bile acid glucuronidation , 2009, Molecular and Cellular Biochemistry.
[2] Xingguo Cheng,et al. Critical role of PPAR-alpha in perfluorooctanoic acid- and perfluorodecanoic acid-induced downregulation of Oatp uptake transporters in mouse livers. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.
[3] B. Staels,et al. Intestine-specific regulation of PPARalpha gene transcription by liver X receptors. , 2008, Endocrinology.
[4] Xian Wang,et al. Peroxisome proliferator‐activated receptor‐δ induces insulin‐induced gene‐1 and suppresses hepatic lipogenesis in obese diabetic mice , 2008, Hepatology.
[5] J. Inoue,et al. PPARalpha gene expression is up-regulated by LXR and PXR activators in the small intestine. , 2008, Biochemical and biophysical research communications.
[6] William J Zuercher,et al. Recent advances in liver X receptor biology and chemistry. , 2008, Current topics in medicinal chemistry.
[7] S. Cotler,et al. Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease. , 2008, World journal of gastroenterology.
[8] N. Ballatori,et al. Ost-Ost is required for bile acid and conjugated steroid disposition in the intestine , kidney , and liver , 2008 .
[9] W. Howard. Effect of Torcetrapib on the Progression of Coronary Atherosclerosis , 2008 .
[10] J. George,et al. Nonalcoholic fatty liver disease: pathogenesis and potential for nuclear receptors as therapeutic targets. , 2008, Molecular pharmaceutics.
[11] J. Repa,et al. Fenofibrate reduces intestinal cholesterol absorption via PPARα-dependent modulation of NPC1L1 expression in mouse Published, JLR Papers in Press, August 28, 2007. , 2007, Journal of Lipid Research.
[12] J. Repa,et al. Fenofibrate reduces intestinal cholesterol absorption via PPARalpha-dependent modulation of NPC1L1 expression in mouse. , 2007, Journal of lipid research.
[13] B. Salman,et al. Peroxisome proliferators-activated alpha agonist treatment ameliorates hepatic damage in rats with obstructive jaundice: an experimental study , 2007, BMC gastroenterology.
[14] J. Plutzky,et al. PPARα in atherosclerosis and inflammation , 2007 .
[15] D. Grobbee,et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. , 2007, The New England journal of medicine.
[16] J. Jukema,et al. Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression Published, JLR Papers in Press, May 24, 2007. , 2007, Journal of Lipid Research.
[17] D. Grobbee,et al. Effect of Torcetrapib on Carotid Atherosclerosis in Familial Hypercholesterolemia , 2007 .
[18] Jean-Claude Tardif,et al. Effect of torcetrapib on the progression of coronary atherosclerosis. , 2007, The New England journal of medicine.
[19] R. Tukey,et al. Expression of the Human UGT1 Locus in Transgenic Mice by 4-Chloro-6-(2,3-xylidino)-2-pyrimidinylthioacetic Acid (WY-14643) and Implications on Drug Metabolism through Peroxisome Proliferator-Activated Receptor α Activation , 2007, Drug Metabolism and Disposition.
[20] K. Eder,et al. Activation of PPARalpha lowers synthesis and concentration of cholesterol by reduction of nuclear SREBP-2. , 2007, Biochemical pharmacology.
[21] K. Eder,et al. PPARγ Ligand Troglitazone Lowers Cholesterol Synthesis in HepG2 and Caco-2 Cells via a Reduced Concentration of Nuclear SREBP-2 , 2006, Experimental biology and medicine.
[22] F. Gonzalez,et al. Ligand-activated PPARβ efficiently represses the induction of LXR-dependent promoter activity through competition with RXR , 2006, Molecular and Cellular Endocrinology.
[23] M. Hayden,et al. Variations on a gene: rare and common variants in ABCA1 and their impact on HDL cholesterol levels and atherosclerosis. , 2006, Annual review of nutrition.
[24] G. Lewis. Determinants of plasma HDL concentrations and reverse cholesterol transport , 2006, Current opinion in cardiology.
[25] Albert K Groen,et al. Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. , 2006, The Journal of clinical investigation.
[26] R. Evans,et al. PPARδ: a dagger in the heart of the metabolic syndrome , 2006 .
[27] P. Mann,et al. Oral Toxicity Study of 2-Pentenenitrile in Rats with Reproductive Toxicity Screening Test , 2006, Drug and chemical toxicology.
[28] R. Collins,et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.
[29] A. Vercelli,et al. Thiazolidinedione treatment inhibits bile duct proliferation and fibrosis in a rat model of chronic cholestasis. , 2005, World journal of gastroenterology.
[30] Jonathan C. Cohen,et al. ABCG5 and ABCG8 require MDR2 for secretion of cholesterol into bile Published, JLR Papers in Press, June 1, 2005. DOI 10.1194/jlr.M500115-JLR200 , 2005, Journal of Lipid Research.
[31] G. Gibbons,et al. A role for PPARalpha in the control of SREBP activity and lipid synthesis in the liver. , 2005, The Biochemical journal.
[32] P. Besnard,et al. The gene encoding the human ileal bile acid-binding protein (I-BABP) is regulated by peroxisome proliferator-activated receptors. , 2005, Biochimica et biophysica acta.
[33] M. Hayden,et al. Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. , 2005, The Journal of clinical investigation.
[34] Jonathan C. Cohen,et al. Expression of ABCG5 and ABCG8 Is Required for Regulation of Biliary Cholesterol Secretion* , 2005, Journal of Biological Chemistry.
[35] B. Staels,et al. Reduced cholesterol absorption upon PPARδ activation coincides with decreased intestinal expression of NPC1L1 Published, JLR Papers in Press, December 16, 2004. DOI 10.1194/jlr.M400400-JLR200 , 2005, Journal of Lipid Research.
[36] B. Staels,et al. Reduced cholesterol absorption upon PPARδ activation coincides with decreased intestinal expression of NPC1L1 Published, JLR Papers in Press, December 16, 2004. DOI 10.1194/jlr.M400400-JLR200 , 2005, Journal of Lipid Research.
[37] P. Dawson,et al. The Heteromeric Organic Solute Transporter α-β, Ostα-Ostβ, Is an Ileal Basolateral Bile Acid Transporter* , 2005, Journal of Biological Chemistry.
[38] Andrew J. Brown,et al. Expression and regulation of sterol 27-hydroxylase (CYP27A1) in human macrophages: a role for RXR and PPARγ ligands , 2005 .
[39] J. Kastelein,et al. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. , 2005, Journal of the American College of Cardiology.
[40] G. Salen,et al. Bile acid biosynthesis , 1974, The American Journal of Digestive Diseases.
[41] Roger A. Davis,et al. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARα, β/δ, and γ , 2004 .
[42] A. Bookout,et al. Prevention of cholesterol gallstone disease by FXR agonists in a mouse model , 2004, Nature Medicine.
[43] L. Csiba,et al. Transcriptional Regulation of Human CYP27 Integrates Retinoid, Peroxisome Proliferator-Activated Receptor, and Liver X Receptor Signaling in Macrophages , 2004, Molecular and Cellular Biology.
[44] Heidi R. Kast-Woelbern,et al. Rosiglitazone Induction of Insig-1 in White Adipose Tissue Reveals a Novel Interplay of Peroxisome Proliferator-activated Receptor γ and Sterol Regulatory Element-binding Protein in the Regulation of Adipogenesis* , 2004, Journal of Biological Chemistry.
[45] Sander M Houten,et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. , 2004, The Journal of clinical investigation.
[46] G. Barish,et al. PPARs and the complex journey to obesity , 2004, Nature Medicine.
[47] Luquan Wang,et al. Materials and Methods Figs. S1 to S4 Tables S1 and S2 References Niemann-pick C1 like 1 Protein Is Critical for Intestinal Cholesterol Absorption , 2022 .
[48] B. Staels,et al. Peroxisome proliferator-activated receptor α (PPARα)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice , 2004 .
[49] G. Gibbons,et al. Inhibition of cholesterol absorption associated with a PPARα-dependent increase in ABC binding cassette transporter A1 in mice Published, JLR Papers in Press, August 1, 2003. DOI 10.1194/jlr.M300042-JLR200 , 2003, Journal of Lipid Research.
[50] G. Gibbons,et al. Inhibition of cholesterol absorption associated with a PPAR alpha-dependent increase in ABC binding cassette transporter A1 in mice. , 2003, Journal of lipid research.
[51] J. Borensztajn,et al. The peroxisome-proliferator-activated receptor alpha agonist ciprofibrate severely aggravates hypercholesterolaemia and accelerates the development of atherosclerosis in mice lacking apolipoprotein E. , 2003, The Biochemical journal.
[52] H. Sone,et al. Cross-talk between peroxisome proliferator-activated receptor (PPAR) alpha and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. II. LXRs suppress lipid degradation gene promoters through inhibition of PPAR signaling. , 2003, Molecular endocrinology.
[53] R. Evans,et al. Peroxisome-Proliferator-Activated Receptor δ Activates Fat Metabolism to Prevent Obesity , 2003, Cell.
[54] S. Grundy,et al. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome. , 2003, The American journal of cardiology.
[55] J. Boyer,et al. Bile salt transporters: molecular characterization, function, and regulation. , 2003, Physiological reviews.
[56] B. Staels,et al. Peroxisome proliferator-activated receptor alpha (PPARalpha)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice. , 2003, The Biochemical journal.
[57] B. Staels,et al. Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor. , 2003, Molecular endocrinology.
[58] B. Staels,et al. Induction of hepatic ABC transporter expression is part of the PPARalpha-mediated fasting response in the mouse. , 2003, Gastroenterology.
[59] Y. Chao,et al. Reduction of Atherosclerosis by the Peroxisome Proliferator-activated Receptor α Agonist Fenofibrate in Mice* , 2002, The Journal of Biological Chemistry.
[60] P. Shah. Low-density lipoprotein lowering and atherosclerosis progression: does more mean less? , 2002, Circulation.
[61] J. Goldstein,et al. Insig-2, a second endoplasmic reticulum protein that binds SCAP and blocks export of sterol regulatory element-binding proteins , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[62] Jonathan C. Cohen,et al. Overexpression of ABCG5 and ABCG8 promotes biliary cholesterol secretion and reduces fractional absorption of dietary cholesterol. , 2002, The Journal of clinical investigation.
[63] M. Fried,et al. Human Apical Sodium-dependent Bile Salt Transporter Gene (SLC10A2) Is Regulated by the Peroxisome Proliferator-activated Receptor α* , 2002, The Journal of Biological Chemistry.
[64] R. Aebersold,et al. Crucial Step in Cholesterol Homeostasis Sterols Promote Binding of SCAP to INSIG-1, a Membrane Protein that Facilitates Retention of SREBPs in ER , 2002, Cell.
[65] Aldons J. Lusis,et al. Identification of macrophage liver X receptors as inhibitors of atherosclerosis , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[66] J. Chiang,et al. Bile acid regulation of gene expression: roles of nuclear hormone receptors. , 2002, Endocrine reviews.
[67] D. Crabb,et al. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. , 2002, Gastroenterology.
[68] H. Hobbs,et al. Regulation of ATP-binding Cassette Sterol Transporters ABCG5 and ABCG8 by the Liver X Receptors α and β* , 2002, The Journal of Biological Chemistry.
[69] T. Willson,et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[70] C. Glass,et al. Conditional Disruption of the Peroxisome Proliferator-Activated Receptor γ Gene in Mice Results in Lowered Expression of ABCA1, ABCG1, and apoE in Macrophages and Reduced Cholesterol Efflux , 2002, Molecular and Cellular Biology.
[71] V. Athyros,et al. Atorvastatin versus Four Statin–Fibrate Combinations in Patients with Familial Combined Hyperlipidaemia , 2002, Journal of cardiovascular risk.
[72] H. Sone,et al. Polyunsaturated Fatty Acids Suppress Sterol Regulatory Element-binding Protein 1c Promoter Activity by Inhibition of Liver X Receptor (LXR) Binding to LXR Response Elements* , 2002, The Journal of Biological Chemistry.
[73] M. Matsuda,et al. Small Heterodimer Partner, an Orphan Nuclear Receptor, Augments Peroxisome Proliferator-activated Receptor γ Transactivation* , 2002, The Journal of Biological Chemistry.
[74] P. Meier,et al. Bile salt transporters. , 2002, Annual review of physiology.
[75] J. Després,et al. Increasing high-density lipoprotein cholesterol: an update on fenofibrate. , 2001, The American journal of cardiology.
[76] F. Gonzalez,et al. Antagonism of the Actions of Peroxisome Proliferator-activated Receptor-α by Bile Acids* , 2001, The Journal of Biological Chemistry.
[77] R. Walczak,et al. Autoregulation of the Human Liver X Receptor α Promoter , 2001, Molecular and Cellular Biology.
[78] B Staels,et al. Fibrates Suppress Bile Acid Synthesis via Peroxisome Proliferator–Activated Receptor-&agr;–Mediated Downregulation of Cholesterol 7&agr;-Hydroxylase and Sterol 27-Hydroxylase Expression , 2001, Arteriosclerosis, thrombosis, and vascular biology.
[79] Gaochao Zhou,et al. 27-Hydroxycholesterol Is an Endogenous Ligand for Liver X Receptor in Cholesterol-loaded Cells* , 2001, The Journal of Biological Chemistry.
[80] Paul T. Tarr,et al. Characterization of the Human ABCG1 Gene , 2001, The Journal of Biological Chemistry.
[81] M. Seishima,et al. Inhibitory action of gemfibrozil on cholesterol absorption in rat intestine. , 2001, Journal of lipid research.
[82] J. Capone,et al. The short heterodimer partner receptor differentially modulates peroxisome proliferator-activated receptor α-mediated transcription from the peroxisome proliferator-response elements of the genes encoding the peroxisomal β-oxidation enzymes acyl-CoA oxidase and hydratase-dehydrogenase , 2001, Molecular and Cellular Endocrinology.
[83] Hitoshi Shimano,et al. Identification of Liver X Receptor-Retinoid X Receptor as an Activator of the Sterol Regulatory Element-Binding Protein 1c Gene Promoter , 2001, Molecular and Cellular Biology.
[84] C. Semenkovich,et al. PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice. , 2001, The Journal of clinical investigation.
[85] J. Auwerx,et al. Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[86] R. Evans,et al. A PPARγ-LXR-ABCA1 Pathway in Macrophages Is Involved in Cholesterol Efflux and Atherogenesis , 2001 .
[87] M. Jaye,et al. PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway , 2001, Nature Medicine.
[88] N. Grishin,et al. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. , 2000, Science.
[89] T. Willson,et al. Peroxisome Proliferator-activated Receptors and Hepatic Stellate Cell Activation* , 2000, The Journal of Biological Chemistry.
[90] Jean-Marc A. Lobaccaro,et al. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRα and LXRβ , 2000 .
[91] D. Mangelsdorf,et al. Role of LXRs in control of lipogenesis. , 2000, Genes & development.
[92] A. Soutar,et al. The effect of peroxisome-proliferator-activated receptor-alpha on the activity of the cholesterol 7 alpha-hydroxylase gene. , 2000, The Biochemical journal.
[93] P. Edwards,et al. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[94] M. Hunt,et al. The Peroxisome Proliferator-activated Receptor α (PPARα) Regulates Bile Acid Biosynthesis* , 2000, The Journal of Biological Chemistry.
[95] N. Hagenbuch,et al. Identification of organic anion transporting polypeptide 4 (Oatp4) as a major full‐length isoform of the liver‐specific transporter‐1 (rlst‐1) in rat liver , 2000, FEBS letters.
[96] B. Levy,et al. Evidence for a Niemann-pick C (NPC) gene family: identification and characterization of NPC1L1. , 2000, Genomics.
[97] C. Gabel,et al. High density lipoprotein deficiency and foam cell accumulation in mice with targeted disruption of ATP-binding cassette transporter-1. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[98] J. Chiang,et al. Peroxisome proliferator-activated receptor alpha (PPARalpha) and agonist inhibit cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription. , 2000, Journal of lipid research.
[99] D. Crabb,et al. Peroxisome proliferator‐activated receptor γ transcriptional regulation is involved in platelet‐derived growth factor–induced proliferation of human hepatic stellate cells , 2000 .
[100] J. Chiang,et al. Peroxisome proliferator-activated receptor a (PPAR a ) and agonist inhibit cholesterol 7 a -hydroxylase gene ( CYP7A1 ) transcription , 2000 .
[101] A. Groen,et al. Mechanisms of Biliary Lipid Secretion and Their Role in Lipid Homeostasis , 2000, Seminars in liver disease.
[102] P. Meier,et al. Hepatic Transport of Bile Salts , 2000, Seminars in liver disease.
[103] Ames,et al. PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA , 2000 .
[104] H. Shimano,et al. A Crucial Role of Sterol Regulatory Element-binding Protein-1 in the Regulation of Lipogenic Gene Expression by Polyunsaturated Fatty Acids* , 1999, The Journal of Biological Chemistry.
[105] P. Shah,et al. Reconstituted HDL containing human apolipoprotein A-1 reduces VCAM-1 expression and neointima formation following periadventitial cuff-induced carotid injury in apoE null mice. , 1999, Biochemical and biophysical research communications.
[106] M. Brown,et al. A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[107] O. Gotoh,et al. Structure, evolution, and liver-specific expression of sterol 12alpha-hydroxylase P450 (CYP8B). , 1999, Journal of biochemistry.
[108] H. Yawo,et al. Identification of a Novel Gene Family Encoding Human Liver-specific Organic Anion Transporter LST-1* , 1999, The Journal of Biological Chemistry.
[109] D. Lütjohann,et al. Removal of cholesterol from extrahepatic sources by oxidative mechanisms. , 1999, Current opinion in lipidology.
[110] S. Kliewer,et al. Structural requirements of ligands for the oxysterol liver X receptors LXRalpha and LXRbeta. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[111] V. Laudet,et al. The Nuclear Receptors Peroxisome Proliferator-activated Receptor α and Rev-erbα Mediate the Species-specific Regulation of Apolipoprotein A-I Expression by Fibrates* , 1998, The Journal of Biological Chemistry.
[112] M. Waterman,et al. Activities of Recombinant Human Cytochrome P450c27 (CYP27) Which Produce Intermediates of Alternative Bile Acid Biosynthetic Pathways* , 1998, The Journal of Biological Chemistry.
[113] R. Hammer,et al. Cholesterol and Bile Acid Metabolism Are Impaired in Mice Lacking the Nuclear Oxysterol Receptor LXRα , 1998, Cell.
[114] A. Gotto,et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.
[115] R. McPherson,et al. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. , 1998, The American journal of cardiology.
[116] Stacey,et al. Structural requirements of ligands for the oxysterol liver X receptors LXR a and LXR b , 1998 .
[117] P. Meier,et al. Substrate specificity of sinusoidal bile acid and organic anion uptake systems in rat and human liver , 1997, Hepatology.
[118] J. Auwerx,et al. Alterations in Lipoprotein Metabolism in Peroxisome Proliferator-activated Receptor α-deficient Mice* , 1997, The Journal of Biological Chemistry.
[119] P. Meier,et al. Isolation of a multispecific organic anion and cardiac glycoside transporter from rat brain. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[120] N. Freimer,et al. Identification of a locus for progressive familial intrahepatic cholestasis PFIC2 on chromosome 2q24. , 1997, American journal of human genetics.
[121] P. Dawson,et al. Primary bile acid malabsorption caused by mutations in the ileal sodium-dependent bile acid transporter gene (SLC10A2). , 1997, The Journal of clinical investigation.
[122] Timothy M. Willson,et al. Activation of the Nuclear Receptor LXR by Oxysterols Defines a New Hormone Response Pathway* , 1997, The Journal of Biological Chemistry.
[123] P. Denéfle,et al. Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits. , 1996, Circulation.
[124] J. Auwerx,et al. Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice. , 1996, The Journal of clinical investigation.
[125] J. Capone,et al. The Orphan Nuclear Hormone Receptor LXR Interacts with the Peroxisome Proliferator-activated Receptor and Inhibits Peroxisome Proliferator Signaling (*) , 1996, The Journal of Biological Chemistry.
[126] D. Lütjohann,et al. Novel pathways for elimination of cholesterol by extrahepatic formation of side-chain oxidized oxysterols. , 1996, Scandinavian journal of clinical and laboratory investigation. Supplementum.
[127] P. Meier. Molecular mechanisms of hepatic bile salt transport from sinusoidal blood into bile. , 1995, The American journal of physiology.
[128] N. Abate,et al. Effects of different phenotypes of hyperlipoproteinemia and of treatment with fibric acid derivatives on the rates of cholesterol 7 alpha-hydroxylation in humans. , 1995, Arteriosclerosis, thrombosis, and vascular biology.
[129] V. Ling,et al. Identification of a sister gene to P-glycoprotein. , 1995, Cancer research.
[130] K. Einarsson,et al. Influence of bezafibrate on hepatic cholesterol metabolism in gallstone patients: Reduced activity of cholesterol 7α‐hydroxylase , 1995, Hepatology.
[131] A. Hofmann. Bile acids as drugs: principles, mechanisms of action and formulations. , 1995, The Italian journal of gastroenterology.
[132] P. Dawson,et al. Cloning and molecular characterization of the ontogeny of a rat ileal sodium-dependent bile acid transporter. , 1995, The Journal of clinical investigation.
[133] K. Umesono,et al. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[134] E. Everett,et al. Molecular cloning, tissue distribution, and expression of a 14-kDa bile acid-binding protein from rat ileal cytosol. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[135] P. Meier,et al. Expression cloning of a rat liver Na(+)-independent organic anion transporter. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[136] P. Borst,et al. Homozygous disruption of the murine MDR2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease , 1993, Cell.
[137] I. Björkhem,et al. Mechanism of degradation of the steroid side chain in the formation of bile acids. , 1992, Journal of lipid research.
[138] K. Anderson,et al. Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease. , 1992, Journal of the American College of Cardiology.
[139] Christine Dreyer,et al. Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors , 1992, Cell.
[140] J. Auwerx,et al. Fibrates influence the expression of genes involved in lipoprotein metabolism in a tissue-selective manner in the rat. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.
[141] A. Tall,et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. , 1990, The New England journal of medicine.
[142] I. Issemann,et al. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators , 1990, Nature.
[143] J. Sjövall,et al. Potential bile acid precursors in plasma--possible indicators of biosynthetic pathways to cholic and chenodeoxycholic acids in man. , 1990, Journal of steroid biochemistry.
[144] V. Fuster,et al. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. , 1990, The Journal of clinical investigation.
[145] J. Sjövall,et al. Occurrence of 3 beta-hydroxy-5-cholestenoic acid, 3 beta,7 alpha-dihydroxy-5-cholestenoic acid, and 7 alpha-hydroxy-3-oxo-4-cholestenoic acid as normal constituents in human blood. , 1988, Journal of lipid research.
[146] M. Axelson,et al. Occurrence of 3~-hydroxy-5-cholestenoic acid, 3@ ,7a-di hydroxy-5-cholestenoic acid, and 7a- hyd roxy-3-oxo-4-c holestenoic acid as nor mal constituents in human blood , 1988 .
[147] K. von Bergmann,et al. Biliary lipid secretion in patients with heterozygous familial hypercholesterolemia and combined hyperlipidemia. Influence of bezafibrate and fenofibrate. , 1988, Journal of lipid research.
[148] A. Gnasso,et al. Effect of gemfibrozil on biliary lipid metabolism in normolipemic subjects. , 1985, Metabolism: clinical and experimental.
[149] S. Grundy,et al. Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man. , 1984, JAMA.
[150] U. Goldbourt,et al. ASSOCIATIONS OF SERUM HIGH DENSITY LIPOPROTEIN AND TOTAL CHOLESTEROL WITH TOTAL, CARDIOVASCULAR, AND CANCER MORTALITY IN A 7-YEAR PROSPECTIVE STUDY OF 10 000 MEN , 1981, The Lancet.
[151] J. Boyer. New concepts of mechanisms of hepatocyte bile formation. , 1980, Physiological reviews.
[152] J. Berndt,et al. Mode of action of the lipid-lowering agents, clofibrate and BM 15075, on cholesterol biosynthesis in rat liver. , 1978, Atherosclerosis.
[153] M C Hjortland,et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. , 1977, The American journal of medicine.
[154] K. Mitropoulos,et al. Cholesterol 7 alpha-hydroxylase. , 1977, Journal of lipid research.
[155] E. Mosbach. Regulation of bile acid synthesis. , 1974, Verhandlungen der Deutschen Gesellschaft fur Innere Medizin.
[156] S. Grundy,et al. Mechanisms of action of clofibrate on cholesterol metabolism in patients with hyperlipidemia. , 1972, Journal of lipid research.
[157] A. Soutar,et al. The effect of peroxisome-proliferator-activated receptor-alpha on the activity of the cholesterol 7 alpha-hydroxylase gene. , 2000, The Biochemical journal.